Innova launches 'conjugation compatible' antibody purification system

By Dan Stanton

- Last updated on GMT

Image: iStock/extender01
Image: iStock/extender01

Related tags Protein

Innova Biosciences says its AbPure Protein A-based system removes the need to undergo an additional step when purifying antibody in preparation for conjugation

Like other downstream systems, the AbPure Magnetic Purification launched this week by Innova comes prepacked with Protein A magnetic beads.

Protein A is often deemed to be the gold standard​ in monoclonal antibody capture resin, but while such systems are good at removing contaminating proteins, they introduce chemicals that can cause problems surrounding compatibility between purification and conjugation processes.

“The purification procedure using protein A was developed in the early 1970’s, predating the widespread use of primary antibody conjugates, thus the needs of conjugation scientists were not necessarily uppermost in the thoughts of those developing purification procedures.”​ Innova’s CEO Nick Gee told Biopharma-Reporter.

“Moreover there are very few chemicals used in purification that meet the requirements of both purification and conjugation scientists.”

Currently antibody conjugate makers must undergo a secondary step to remove interfering chemicals introduced during the purification procedure, following the removal of contaminating proteins using a protein A-based system.

But according to Gee, Innova’s new system has “completely re-engineered the reagents used in antibody purification procedures so that the final purified antibody can be used in any conjugation procedure.”

As well as drugmakers, Innova is targeting the platform towards anyone who needs to attach a label – an enzyme, dye, particle, fluorescent protein, etc - to a purified antibody. “This includes researchers, companies selling antibody conjugates, and companies selling products that contain conjugates,”​ said Gee.

Protein A contract for Purolite

In further downstream news this week, Welsh Protein A resin maker Purolite has struck a deal to work with the UK’s Centre for Process Innovation – a government funded model aiding small and mid-sized biomanufacturing firms to develop products and bioprocesses through a £38m National Biologics Manufacturing Centre.

CPI will perform, in partnership with an unnamed biopharma firm, an evaluation study of Purolite’s Praesto agarose-based Protein A chromatography range of resins. The study will also use analytical assays supplied by PerkinElmer.

Just last week​, CPI inked a long-term deal to license cell lines from UK-based gene editing firm Horizon Discovery.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers